Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHA:688393)

SHA:688393 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	365.04	464.8	490.94	504.62	437.44	374.57
Other Revenue	5.99	5.99	6.35	2.76	1.55	0.87
Revenue	371.03	470.79	497.29	507.38	438.99	375.43
Revenue Growth (YoY)	-25.11%	-5.33%	-1.99%	15.58%	16.93%	5.71%
Cost of Revenue	137.98	159.61	161.87	148.97	98.6	76.19
Gross Profit	233.05	311.18	335.42	358.41	340.39	299.24
Selling, General & Admin	224.22	262.83	258.79	260.14	232.02	185.72
Research & Development	42.97	45.47	62.69	67.39	45.9	27.73
Other Operating Expenses	2.08	1.78	1.9	4.04	1.97	1.88
Operating Expenses	270.35	315.75	327.88	336.92	281.59	221.35
Operating Income	-37.3	-4.56	7.54	21.49	58.8	77.89
Interest Expense	-0.51	-0.65	-0.81	-1.36	-0.38	-
Interest & Investment Income	7.54	11.99	8.8	7.69	19.12	10.29
Earnings From Equity Investments	0	0	0	-0	-	-
Currency Exchange Gain (Loss)	-0.02	-0.02	-0.08	0.14	-0.06	-0.1
Other Non Operating Income (Expenses)	1.26	-0.25	-0.31	-0.28	-0.38	-0.21
EBT Excluding Unusual Items	-29.01	6.52	15.14	27.68	77.09	87.87
Impairment of Goodwill	-	-	-3.06	-	-	-
Gain (Loss) on Sale of Investments	3.53	2.53	5.14	-3.14	6.12	0.46
Gain (Loss) on Sale of Assets	0.1	0.16	-0.64	0.15	-0.61	-0.55
Asset Writedown	-4.61	-3.69	-	-	-	-
Other Unusual Items	2.11	3.92	0.27	4.11	6.12	12.08
Pretax Income	-27.88	9.43	16.85	28.79	88.72	99.85
Income Tax Expense	-7.81	-5.47	-4.17	-0.54	13.44	16.23
Earnings From Continuing Operations	-20.07	14.9	21.02	29.33	75.28	83.62
Minority Interest in Earnings	0.96	6.39	19.04	13.36	4.49	1.12
Net Income	-19.11	21.29	40.06	42.69	79.78	84.75
Net Income to Common	-19.11	21.29	40.06	42.69	79.78	84.75
Net Income Growth	-	-46.85%	-6.18%	-46.48%	-5.87%	14.54%
Shares Outstanding (Basic)	90	93	93	93	94	78
Shares Outstanding (Diluted)	90	93	95	95	94	78
Shares Change (YoY)	-6.37%	-2.94%	0.53%	1.09%	20.71%	11.39%
EPS (Basic)	-0.21	0.23	0.43	0.46	0.85	1.09
EPS (Diluted)	-0.21	0.23	0.42	0.45	0.85	1.09
EPS Growth	-	-45.24%	-6.67%	-47.06%	-22.02%	2.83%
Free Cash Flow	22.41	-20.1	-20.62	-62.45	-83.73	28.98
Free Cash Flow Per Share	0.25	-0.22	-0.22	-0.66	-0.89	0.37
Dividend Per Share	0.100	0.100	0.150	0.140	0.270	0.280
Dividend Growth	-33.33%	-33.33%	7.14%	-48.15%	-3.57%	-
Gross Margin	62.81%	66.10%	67.45%	70.64%	77.54%	79.71%
Operating Margin	-10.05%	-0.97%	1.52%	4.23%	13.39%	20.75%
Profit Margin	-5.15%	4.52%	8.05%	8.42%	18.17%	22.57%
Free Cash Flow Margin	6.04%	-4.27%	-4.15%	-12.31%	-19.07%	7.72%
EBITDA	0.97	33.68	45.74	53.84	75.33	88.35
EBITDA Margin	0.26%	7.15%	9.20%	10.61%	17.16%	23.53%
D&A For EBITDA	38.27	38.24	38.2	32.35	16.53	10.46
EBIT	-37.3	-4.56	7.54	21.49	58.8	77.89
EBIT Margin	-10.05%	-0.97%	1.52%	4.23%	13.39%	20.75%
Effective Tax Rate	-	-	-	-	15.15%	16.25%
Revenue as Reported	371.03	470.79	497.29	507.38	438.99	375.43

Source: S&P Global Market Intelligence. Standard template. Financial Sources.